clinical trial · NCT04542057
A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
Chronic Obstructive Pulmonary DiseaseEnsifentrinePlacebo
brief summary
The purpose of this study is to determine if ensifentrine is safe and effective for the treatment of patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
started
Sep 22, 2020
primary completion
May 3, 2022
completion
Jul 6, 2022
last updated
Oct 16, 2023
official title
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol